Mektovi

• Mektovi (binimetinib) is a MEK inhibitor, a type of targeted cancer therapy.
• It is primarily used in combination with encorafenib to treat unresectable or metastatic melanoma with specific BRAF V600E or V600K mutations.
• The drug works by blocking the MEK proteins in the MAPK signaling pathway, which helps to slow or stop cancer cell growth.
• Mektovi is an oral medication, typically taken twice daily.
• Patients undergoing Mektovi treatment require careful monitoring for potential serious side effects, including heart, eye, and skin problems.

What is Mektovi and How It Works?

Mektovi (binimetinib) is a targeted therapy approved for the treatment of certain cancers. It is classified as a mitogen-activated protein kinase (MEK) inhibitor. MEK proteins are part of the RAS/RAF/MEK/ERK signaling pathway, which is critical for cell growth, proliferation, and survival. In many cancers, particularly melanoma, this pathway can become overactive due to specific genetic mutations, leading to uncontrolled cell division.

Mektovi works by selectively inhibiting MEK1 and MEK2, two key proteins within this pathway. By blocking these proteins, Mektovi disrupts the abnormal signaling cascade that drives cancer cell growth in individuals with BRAF V600E or V600K mutations. This mechanism helps to slow down or stop the proliferation of cancer cells. Approximately 40-50% of melanomas harbor BRAF mutations, making targeted therapies like Mektovi crucial for a significant patient population. (Source: American Cancer Society)

Mektovi Uses and Drug Information

Mektovi is indicated, in combination with encorafenib (a BRAF inhibitor), for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. This combination therapy targets two different points in the same signaling pathway, enhancing efficacy and helping to overcome potential resistance mechanisms. It is crucial that patients undergo genetic testing to confirm the presence of these specific BRAF mutations before initiating treatment with Mektovi.

Regarding Mektovi drug information, it is an oral medication taken as a tablet. Adherence to the prescribed dosage and schedule is vital for treatment effectiveness. Patients typically take Mektovi twice daily, approximately 12 hours apart, with or without food. It is important to avoid missing doses and to follow the healthcare provider’s instructions precisely. Regular monitoring by a healthcare professional is necessary to assess the drug’s effectiveness and manage any potential side effects.

• Dosage: The typical recommended dose is 45 mg orally twice daily.
• Administration: Tablets should be swallowed whole. Do not chew, crush, or split them.
• Combination Therapy: Always used in conjunction with encorafenib, an oral BRAF inhibitor.

Mektovi Side Effects and Warnings

Like all medications, Mektovi can cause side effects, ranging from mild to severe. Common Mektovi side effects and warnings include fatigue, nausea, diarrhea, vomiting, abdominal pain, and skin rash. Patients may also experience muscle pain, fever, and changes in laboratory test results, such as elevated liver enzymes.

More serious side effects can occur and require immediate medical attention. These include, but are not limited to, cardiomyopathy (heart problems, including heart failure), ocular toxicity (eye problems such as retinal detachment, uveitis, or vision changes), dermatologic reactions (severe skin reactions), hepatotoxicity (liver problems), rhabdomyolysis (muscle breakdown), and new primary malignancies (risk of developing new cancers). Due to the potential for these serious adverse events, patients receiving Mektovi are closely monitored by their healthcare team throughout the treatment period. Any unusual symptoms or changes in health should be reported to a doctor promptly.